Non‐serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (very low certainty).
1 finding from 1 review
Non‐serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin plus non‐absorbable… changes non‐serious adverse events ‐ total number of participants compared with non‐absorbable disaccharides alone (very low certainty).
1 finding from 1 review
Non‐serious adverse events ‐ total number of particiapnts · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of particiapnts compared with placebo/no intervention (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events (number of serious adverse events) · patients with laparoscopic cholecystectomy.
It is very uncertain whether the intervention changes serious adverse events (number of serious adverse events) (very low certainty).
1 finding from 1 review
SAEs · psoriatic arthritis
Methotrexate showed no clear difference in serious adverse events (SAEs) assessed by number of events compared with placebo (low certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
It is very uncertain whether adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver… changes adverse events considered non‐serious (number of participants) compared with liver transplantation (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
It is very uncertain whether E1B‐deleted (dl1520) adenovirus changes adverse events considered non‐serious (number of participants) compared with percutaneous ethanol injection (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes adverse events considered non‐serious (number of participants) compared with best supportive care alone (very low certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · patients with osteoarthritis
1 finding from 1 review
Number of participants experiencing any serious adverse events · patients with osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants experiencing any serious adverse events · patients with osteoarthritis
It is very uncertain whether tramadol alone changes number of participants experiencing any serious adverse events compared with NSAIDs (very low certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · patients with osteoarthritis
It is very uncertain whether tramadol alone changes number of participants experiencing any serious adverse events compared with other opioids (very low certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · patients with osteoarthritis
1 finding from 1 review
Number of participants experiencing any serious adverse events · patients with osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants experiencing any serious adverse events · Patients with osteoarthritis of the knee or hip
Tramadol alone may leads to higher number of participants experiencing any serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Number of participants experiencing any serious adverse events · patients with osteoarthritis of the ankle
1 finding from 1 review
Number of participants experiencing any serious adverse events · stable COPD
Long‐acting muscarinic antagonist (LAMA) plus long‐acting… showed no clear difference in serious adverse events (number of people experiencing ≥ 1 SAEs) compared with LABA plus inhaled corticosteroid (ICS) (high certainty).
1 finding from 1 review
Serious adverse events (leflunomide) assessed by number of events · psoriatic arthritis
1 finding from 1 review
Serious adverse events (ciclosporin A) assessed by number of events · psoriatic arthritis
1 finding from 1 review
Number of participants experiencing any serious adverse events · the management of chronic obstructive pulmonary disease
Multi‐component intervention showed no clear difference in adverse events: number of people experiencing a serious adverse event compared with other intervention or routine, usual care or control treatment (low certainty).
1 finding from 1 review